Published in Exp Ther Med on January 01, 2010
Natural humoral immune response to ribosomal P0 protein in colorectal cancer patients. J Transl Med (2015) 0.81
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer (2008) 7.99
'Hard' and 'soft' principles defining the structure, function and regulation of keratin intermediate filaments. Curr Opin Cell Biol (2002) 3.00
Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res (2005) 2.31
Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res (2004) 2.03
Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin Cancer Res (1998) 1.68
Death without caspases, caspases without death. Trends Cell Biol (2004) 1.67
Clinical utility of cytokeratins as tumor markers. Clin Biochem (2004) 1.63
Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer. APMIS (2008) 1.42
Vital functions for lethal caspases. Oncogene (2005) 1.40
Cytokeratin markers come of age. Tumour Biol (2007) 1.28
Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res (2009) 1.25
Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance. Breast Cancer Res (2008) 1.09
Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J Cell Biochem (2002) 1.07
Specificity and basis of the tissue polypeptide antigen. Cancer Detect Prev (1983) 1.04
The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21-1) in human lung cancer cell lines. Int J Cancer (2001) 1.00
Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. Br J Cancer (2009) 0.97
Circulating cytokeratin 18 fragment m65-a potential marker of malignancy in colorectal cancer patients. J Gastrointest Surg (2009) 0.91
Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients. Eur J Surg Oncol (2009) 0.88
The versatility of cytokeratins as tumor markers. Tumour Biol (2000) 0.86
Time to metastatic relapse and breast cancer cells dissemination in bone marrow at metastatic relapse. Clin Exp Metastasis (2008) 0.82
Spontaneous changes in tumour cell dissemination to bone marrow in colorectal cancer. Colorectal Dis (2009) 0.81
Computer modeling of cytokeratin release in clinical oncology. Anticancer Res (1997) 0.78
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol (2011) 1.88
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood (2012) 1.77
Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood (2011) 1.40
The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood (2012) 1.35
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood (2011) 1.34
Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest (2003) 1.21
A better platinum-based anticancer drug yet to come? Anticancer Agents Med Chem (2010) 1.12
Synthesis of compounds with antiproliferative activity as analogues of prenylated natural products existing in Brazilian propolis. Eur J Med Chem (2006) 0.96
Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization. J Mol Diagn (2009) 0.95
Anticancer drug cis-4-hydroxy-L-proline: Correlation of preclinical toxicology with clinical parameters of liver function. Mol Med Rep (2011) 0.95
The analysis of organic anion transporting polypeptide (OATP) mRNA and protein patterns in primary and metastatic liver cancer. Cancer Biol Ther (2011) 0.91
Circulating cytokeratin 18 fragment m65-a potential marker of malignancy in colorectal cancer patients. J Gastrointest Surg (2009) 0.91
In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines. Clin Transl Oncol (2011) 0.90
Comparison of (11)C-acetate positron emission tomography and (67)Gallium citrate scintigraphy in patients with hepatocellular carcinoma. Liver Int (2006) 0.89
Mechanisms of cytotoxicity of anticancer titanocenes. Anticancer Agents Med Chem (2010) 0.87
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan. Eur J Haematol (2006) 0.86
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. Am J Hematol (2012) 0.86
Activation of Na+/H+ exchanger 1 by neurotensin signaling in pancreatic cancer cell lines. Biochem Biophys Res Commun (2010) 0.85
Neurotensin signaling induces intracellular alkalinization and interleukin-8 expression in human pancreatic cancer cells. Mol Oncol (2009) 0.85
Alterations of phosphoproteins in NCI-H526 small cell lung cancer cells involved in cytotoxicity of cisplatin and titanocene Y. Neoplasia (2012) 0.85
Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofibrosis. Eur J Haematol (2008) 0.84
The sulfatase pathway for estrogen formation: targets for the treatment and diagnosis of hormone-associated tumors. J Drug Deliv (2013) 0.82
In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds. Clin Pharmacol (2010) 0.82
Anticancer activity and mode of action of titanocene C. Invest New Drugs (2010) 0.82
In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent. Met Based Drugs (2009) 0.81
Overexpression of CYP3A4 in a COLO 205 Colon Cancer Stem Cell Model in vitro. Cancers (Basel) (2011) 0.81
Dependence of Relative Expression of NTR1 and EGFR on Cell Density and Extracellular pH in Human Pancreatic Cancer Cell Lines. Cancers (Basel) (2011) 0.78
Picoplatin pharmacokinetics and chemotherapy of non-small cell lung cancer. Expert Opin Drug Metab Toxicol (2013) 0.77
Immunomagnetic CD45 depletion does not improve cytokeratin 20 RT-PCR in colorectal cancer. Clin Chem Lab Med (2007) 0.77
Effects of 1alpha,25-dihydroxy-vitamin D3 pretreatment and MAP kinase inhibitor PD 98059 on response of osteoblasts to prostate-derived osteoblastic factors. Oncol Rep (2003) 0.77
Successful treatment sequence incorporating bevacizumab for therapy of polyneuropathy in two patients with POEMS syndrome. Leuk Res (2012) 0.77
Measurement of bone turnover in prostate cancer patients receiving intermittent androgen suppression therapy. Open Access J Urol (2010) 0.77
Steroid hormone metabolizing enzymes in benign and malignant human bone tumors. Expert Opin Drug Metab Toxicol (2010) 0.76
Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents. Anticancer Drugs (2009) 0.76
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol (2015) 0.76
Somatostatin receptor scintigraphy with 111In-DOTA-lanreotide and 111In-DOTA-Tyr3-octreotide in patients with stage IV melanoma: in-vitro and in-vivo results. Melanoma Res (2005) 0.75
Effects of two disiloxanes ALIS-409 and ALIS-421 on chemoprevention in model experiments. Anticancer Res (2013) 0.75
Anticancer effects of the organosilicon multidrug resistance modulator SILA 421. Anticancer Agents Med Chem (2012) 0.75